Literature DB >> 12479395

Neutralizing B cell response in measles.

Fabienne B Bouche1, Oliver T Ertl, Claude P Muller.   

Abstract

Co-evolving mechanisms of immune clearance and of immune suppression are among the hallmarks of measles. B cells are major targets cells of measles virus (MV) infection. Virus interactions with B cells result both in immune suppression and a vigorous antibody response. Although antibodies fully protect against (re)infection, their importance during the disease and in the presence of a potent cellular response is less well understood. Specific serum IgM appears with onset of rash and confirms clinical diagnosis. After isotype switching, IgG1 develops and confers life-long protection. The most abundant antibodies are specific for the nucleoprotein, but neutralizing and protective antibodies are solely directed against the two surface glycoproteins, the hemagglutinin and the fusion protein. Major neutralizing epitopes have been mapped mainly on the hemagglutinin protein with monoclonal antibodies, producing an increasingly comprehensive map of functional domains.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12479395     DOI: 10.1089/088282402760312331

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  41 in total

1.  The association of CD46, SLAM and CD209 cellular receptor gene SNPs with variations in measles vaccine-induced immune responses: a replication study and examination of novel polymorphisms.

Authors:  Inna G Ovsyannikova; Iana H Haralambieva; Robert A Vierkant; Megan M O'Byrne; Robert M Jacobson; Gregory A Poland
Journal:  Hum Hered       Date:  2011-11-11       Impact factor: 0.444

Review 2.  Advances in the field of lentivector-based transduction of T and B lymphocytes for gene therapy.

Authors:  Cecilia Frecha; Camille Lévy; François-Loïc Cosset; Els Verhoeyen
Journal:  Mol Ther       Date:  2010-08-24       Impact factor: 11.454

Review 3.  Waning and aging of cellular immunity to Bordetella pertussis.

Authors:  Inonge van Twillert; Wanda G H Han; Cécile A C M van Els
Journal:  Pathog Dis       Date:  2015-09-13       Impact factor: 3.166

4.  Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization.

Authors:  Rik L de Swart; Selma Yüksel; Albert D M E Osterhaus
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

5.  Differential cellular immune responses to wild-type and attenuated edmonston tag measles virus strains are primarily defined by the viral phosphoprotein gene.

Authors:  Iana H Haralambieva; Inna G Ovsyannikova; Neelam Dhiman; Robert A Vierkant; Robert M Jacobson; Gregory A Poland
Journal:  J Med Virol       Date:  2010-11       Impact factor: 2.327

6.  Inactivated Recombinant Rabies Viruses Displaying Canine Distemper Virus Glycoproteins Induce Protective Immunity against Both Pathogens.

Authors:  Renata da Fontoura Budaszewski; Andrew Hudacek; Bevan Sawatsky; Beate Krämer; Xiangping Yin; Matthias J Schnell; Veronika von Messling
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

Review 7.  The Density Code for the Development of a Vaccine?

Authors:  Wei Cheng
Journal:  J Pharm Sci       Date:  2016-09-17       Impact factor: 3.534

8.  Association of persistent wild-type measles virus RNA with long-term humoral immunity in rhesus macaques.

Authors:  Ashley N Nelson; Wen-Hsuan W Lin; Rupak Shivakoti; Nicole E Putnam; Lisa Mangus; Robert J Adams; Debra Hauer; Victoria K Baxter; Diane E Griffin
Journal:  JCI Insight       Date:  2020-02-13

9.  Comparison of the immune responses induced by chimeric alphavirus-vectored and formalin-inactivated alum-precipitated measles vaccines in mice.

Authors:  M Jeff Bergen; Chien-Hsiung Pan; Catherine E Greer; Harold S Legg; John M Polo; Diane E Griffin
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  The receptor-binding site of the measles virus hemagglutinin protein itself constitutes a conserved neutralizing epitope.

Authors:  Maino Tahara; Shinji Ohno; Kouji Sakai; Yuri Ito; Hideo Fukuhara; Katsuhiro Komase; Melinda A Brindley; Paul A Rota; Richard K Plemper; Katsumi Maenaka; Makoto Takeda
Journal:  J Virol       Date:  2013-01-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.